P01 CA104177-030002/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Zhang G, et al. Clin Cancer Res. 2008 Sep 1;14(17):5385-99. doi: 10.1158/1078-0432.CCR-08-0469. Clin Cancer Res. 2008. PMID: 18765530 Free PMC article.

Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.

Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P. Martin AP, et al. Mol Pharmacol. 2008 Sep;74(3):807-22. doi: 10.1124/mol.108.047365. Epub 2008 Jun 10. Mol Pharmacol. 2008. PMID: 18544666 Free PMC article.

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P. Park MA, et al. Mol Cancer Ther. 2008 Sep;7(9):2633-48. doi: 10.1158/1535-7163.MCT-08-0400. Mol Cancer Ther. 2008. PMID: 18790746 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters